Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 10,300 shares, a decline of 86.7% from the December 31st total of 77,600 shares. Based on an average daily trading volume, of 153,100 shares, the days-to-cover ratio is currently 0.1 days.

Bioxytran Stock Up 3.4 %

Shares of BIXT traded up $0.00 during mid-day trading on Thursday, hitting $0.10. 56,000 shares of the company traded hands, compared to its average volume of 227,700. The business has a 50 day moving average of $0.09 and a 200 day moving average of $0.10. The company has a market capitalization of $8.68 million, a PE ratio of -10.00 and a beta of -0.55. Bioxytran has a 1-year low of $0.06 and a 1-year high of $0.15.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.